



COVID-19 CORE CASE REPORT FORM

ACUTE RESPIRATORY INFECTION CLINICAL CHARACTERISATION DATA TOOL

DESIGN OF THIS CASE REPORT FORM (CRF)

This CRF is set up in modules to be used for recording data on the ISARIC COVID-19 Core Database or for independent studies.

Module 1 and Module 2 complete on the first day of presentation/admission or on first day of <u>COVID-19 assessment</u>. **Module 2** also complete on first day of admission to ICU or high dependency unit, or if receiving critical care in any ward, and on any days that research specific samples are taken. In addition, complete daily if of interest for local, specific analysis. Continue to follow-up patients who transfer between wards.

Module 3 (Outcome) complete at discharge or death

GENERAL GUIDANCE

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected prospectively or retrospectively if the patient is enrolled after the admission date.
- For more detailed guidance on how to complete these forms, please refer to the CRF Completion Guideline
- Participant Identification Numbers consist of a 3 or 5 digit site code and a 4 digit participant number. You can obtain a site code and register on the data management system by contacting ncov@isaric.org. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporate alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page.
- Printed paper CRFs may be used for later transfer of the data onto the electronic database.
- For participants who return for re-admission to the same site, **start a new form with a different Participant Identification Number**. Please check "YES-admitted previously to this facility" in the RE-ADMISSION section. Enter as 2 separate entries in the electronic database.
- For participants who transfer between two sites that are both collecting data on this form, it is preferred to have
 the data entered by a single site as a single admission, under the same Participant Identification Number. When
 this is not possible, the first site should record "Transfer to other facility" as an OUTCOME, and the second site
 should start a new form with a new patient number and indicate "YES-transferred from other facility" READMISSION.
- Complete every line of every section, except where the instructions say to skip a section based on a response.
- Selections with circles (○) are single selection answers (choose one answer only). Selections with square boxes (□) are multiple selection answers (choose as many answers as are applicable).
- Mark 'Not done' for any results of laboratory values that are not available, not applicable or unknown.
- Avoid recording data outside of the dedicated areas. Sections are available for recording additional information.
- If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- Please transfer all paper CRF data to the electronic database. All paper CRFs needs to be stored locally, do not send any forms to us. Data are accepted only via secure electronic database.
- Please enter data on the electronic data capture system at https://ncov.medsci.ox.ac.uk/. If your site would like to collect data independently, we are happy to support the establishment of locally hosted databases.
- Please contact us at <u>ncov@isaric.org</u> if you need help with databases, if you have comments and to let us know that you are using the forms.





MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM

CLINICAL INCLUSION CRITERIA
Suspected or confirmed novel coronavirus (COVID-19) infection: OYES ONO
DEMOGRAPHICS
Clinical centre name:Country:
Enrolmentdate /first COVID-19 assessment date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
Ethnic group (check all that apply): □Arab □Black □East Asian □South Asian □ West Asian □Latin American □White □Aboriginal/First Nations □Other: OUnknown
Employed as a Healthcare Worker? OYES ONO OUnknown Employed in a microbiology laboratory? OYES ONO OUnknown
Sex at Birth: OMale OFemale ONot specified/Unknown Age [][]years OR [][]months
Pregnant? OYES ONO OUnknown If YES: Gestational weeks assessment: [][] weeks
POST PARTUM (within 6 weeks of delivery)? OYES ONO OUnknown (if NO or Unknown skip this section)
Pregnancy Outcome: OLive birth OStill birth Delivery date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
Baby tested for COVID-19/SARS-CoV-2 infection? OYES ONO OUnknown
If YES, result of test: OPositive ONegative OUnknown (If Positive, complete a separate CRF for baby)
INFANT – Less than 1 year old? OYES ONO (If NO skip this section)
Birth weight: []C]Okg or Olbs OUnknown
Gestational outcome: O Term birth (≥37wk GA) OPreterm birth (<37wk GA) OUnknown
Breastfed? OYES-currently breastfeeding OYES-breastfeeding discontinued ONO OUnknown
Vaccinations appropriate for age/country? OYES ONO OUnknown
ONSET & ADMISSION
Onset date of first/earliest symptom: [_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_)
Most recent presentation/admission date at this facility: <code>[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]</code>
RE-ADMISSION
Was the patient admitted previously or transferred from any other facility during this illness episode?
OYES-admitted previously to this facility OYES—transferred from other facility ONO OUnknown
Has this patient's data been previously collected under a different patient number? OYES ONO OUnknown
If YES, Participant Identification number (PIN):
Is the patient being re-admitted with or due to COVID-19? (Please only add re-admission episodes for COVID related complications or patients remaining positive). Assign new subject ID OYES ONO OUnknown
Previous participant ID: OUnknown
Number of re-admissions: (record as a new patient for each re-admission)
Please provide reason for readmission:





MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM								
SIGNS AND SYMPTOMS AT HO	SIGNS AND SYMPTOMS AT HOSPITAL ADMISSION (first available data at presentation/admission – within 24 hours)							
Temperature: [][].[] O °C <i>or</i> O °F								
HR: [][]beats/min	ute	RR: [][]breaths/minut	te					
Systolic BP: [][]mmHg	Diastolic BP: [][_][]mmHg						
Oxygen saturation: [][][_]% On: ORoom air OO>	kygen therapy O Unknown						
Sternal capillary refill time >2sec.	OYES ONO OUnknown	Height: [][]cm	Weight: [][]kg					
CICNE AND EVANDTONE ON A	MISSION / Link - Linkny	own						
SIGNS AND SYMPTOMS ON AD History of fever	OYES ONO OUnk	Fatigue / Malaise	OYES ONO OUnk					
Cough OYES - non-productive	OYES - productive	Anorexia	OYES ONO OUnk					
OYES - with haemoptysis		Altered consciousness/confusion	OYES ONO OUnk					
Sore throat	OYES ONO OUnk	Muscle aches (myalgia)	OYES ONO OUnk					
Runny nose (rhinorrhoea)	OYES ONO OUnk	Joint pain (arthralgia)	OYES ONO OUnk					
Wheezing	OYES ONO OUnk	Inability to walk	OYES ONO OUnk					
Shortness of breath	OYES ONO OUnk	Abdominal pain	OYES ONO OUnk					
Lower chest wall indrawing	OYES ONO OUnk	Diarrhoea	OYES ONO OUnk					
Chest pain	OYES ONO OUnk	Vomiting / Nausea	OYES ONO OUnk					
Conjunctivitis	OYES ONO OUnk	Skin rash	OYES ONO OUnk					
Lymphadenopathy	OYES ONO OUnk	Bleeding (Haemorrhage)	OYES ONO OUnk					
Headache	OYES ONO OUnk	If YES, specify site(s):						
Loss of smell (Anosmia)	OYES ONO OUnk	Other symptom(s)	OYES ONO OUnk					
Loss of taste (Ageusia)	OYES ONO OUnk	If YES, specify:						
Seizures	OYES ONO OUnk							
VACCINATIONS								
Covid-19 vaccination OYES ONO OUNK Estimated date of most recent dose: D_] D_] / D_]								
If YES, number of doses received:								
If YES, specify type of the most recent vaccine:								
If more than one dose has been given, specify all types of vaccine previously received:								

Influenza vaccination within the last 6 months: OYES ONO OUnknown

PRE-ADMISSION MEDICATION (taken within 14 days prior to admission/presentation at healthcare facility)							
Steroids	OYES ONO OUnk If YES, OOral OInhaled OUnk						
Other immunosuppressant agents (not oral steroids)	OYES ONO OUnk						
Antibiotics	OYES ONO OUnk If YES, agent(s):						
Antivirals	OYES ONO OUnk If YES, agent(s):						
Other targeted COVID-19 Medications	OYES ONO OUnk If YES, agent(s):						





PARTICIPANT IDENTIFICATION #:	[]	I 1	II 1	II I	II .]	[]	r 1	I 1	Γ	•

MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM

CO-MORBIDITIES AND RISK FACTORS (existing prior to admission and ongoing)								
Chronic cardiac disease (not hypertension)	OYES ONO OUnk	Chronic hematologic disease OYES ONO C) Unk					
		AIDS / HIV OYES-on ART OYES-not on ART ONO	O Unk					
Hypertension	OYES ONO OUnk	If YES, most recent CD4 count:						
		O < 200 O 200-< 500 O ≥ 500 cells/uL O Unk						
		Diabetes Mellitus OYES-Type 1 OYES -Type 2						
	OVEC ONO Other	OYES -Gestational ONO	O Unk					
Chronic pulmonary disease (not asthma)	OYES ONO OUnk	If YES, HbA1C results (within last 6 months):						
		Units: Ommol/mol Ommol/L O%						
Asthma (physician diagnosed)	OYES ONO OUnk	Rheumatologic disorder OYES ONO C) Unk					
Chronic kidney disease	OYES ONO OUnk	Dementia OYES ONO C) Unk					
Obesity (as defined by clinical staff)	OYES ONO OUnk	Tuberculosis OYES ONO C) Unk					
Moderate or severe liver disease	OYES ONO OUnk	Malnutrition OYES ONO C	D Unk					
Mild liver disease	OYES ONO OUnk	Smoking OYES ONever smoked OFormer smoker	O Unk					
Asplenia	OYES ONO OUnk	Other relevant risk factor(s) OYES ONO	OUnk					
Chronic neurological disorder	OYES ONO OUnk	If YES, specify:						
Malignant neoplasm	OYES ONO OUnk							

MODULE 2: CASE REPORT FORM ON ADMISSION, CRITICAL CARE, RESEARCH SAMPLING

Complete on the day of admission or first COVID-19 investigation, and on the first day of ICU admission (if different from day of admission). In addition, complete for days when biochemical results are available.

SIGNS AND SYMPTOMS (Record the worst value between 00:00 to 24:00 on day of assessment)(worst=furthest from normal range)
DATE OF ASSESSMENT (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
Highest temperature: [][].[] O°C or O°F HR: [][]beats/minute RR: [][]breaths/minute
Systolic BP: [][]mmHg Diastolic BP: [][]mmHg
Oxygen saturation SaO ₂ [][]%
Any supplemental oxygen: OYES ONO OUnknown If yes,
FiO ₂ (0.21-1.0) [].[] or [][] % or [][]L/min (Highest L/min)
PaO ₂ (at time nearest to the FiO ₂ recorded at top of page) [][]OkPa or OmmHg ONot done
PaO₂ sample type: OArterial OCapillary OVenous OUnknown
From same blood gas record as PaO ₂ :
PCO ₂ OkPa <i>or</i> OmmHg pH HCO ₃ mEq/L Base excess mmol/L
Sternal capillary refill time >2seconds OYES ONO OUnknown
AVPU: Alert [] Verbal[] Pain [] Unresponsive [] Glasgow Coma Score (GCS / 15) [][]
Richmond Agitation-Sedation Scale (RASS) []
Mean Arterial Blood Pressure [][]mmHg OUnknown
Urine flow rate [][][]mL/24 hours O Check if estimated OUnknown





MODULE 2: CASE REPORT FORM ON ADMISSION, CRITICAL CARE, RESEARCH SAMPLING

Complete on the day of admission or first COVID-19 investigation, and on the first day of ICU admission (if different from day of admission). In addition, depending on available resources, complete every day for a maximum of 14 days, or for days when biochemical results are available.

Is the patient currently receiv	ing, or has received (between	en 00:00 to	24:00 on day of assessment	t)					
Current admission to ICU/ITU	/IMC/HDU? OYES ONO	OUnknown							
High-flow nasal cannula oxygo	ligh-flow nasal cannula oxygen therapy? OYES ONO OUnknown								
Non-invasive ventilation (Any)? OYES ONO OUnknow	n If YES:	OBIPAP OCPAP OOther	OUnknown					
Invasive ventilation?	YES ONO OUnknown								
Prone positioning?	YES ONO OUnknown If y	es, O durin	g invasive ventilation O whil	st self-ventilating O Unknow	vn				
Inhaled Nitric Oxide?	YES ONO OUnknown								
Tracheostomy inserted? C	YES ONO OUnknown								
Extra corporeal life support (E	ECLS/ ECMO)? OYES O	NO O Unkn	own If YES: OVV OAV C	Central OUnknown					
Renal replacement therapy (R	RRT) or dialysis? OYES ON	IO O Unkno	own						
Any vasopressor/inotropic su	pport? OYES ONO OUnk	known <i>(if N</i>	O, select NO for the next 3 q	uestions)					
Dopamine <5μg/kg/min C	OR Dobutamine OR milrino	ne OR levos	simendan:	O YES	ONO				
Dopamine 5-15μg/kg/min	n OR Epinephrine/Norepine	ephrine < 0.	1μg/kg/min OR vasopressir	OR phenylephrine: OYES	ONO				
Dopamine >15μg/k/min C	OR Epinephrine/Norepinep	hrine > 0.1	ւg/kg/min։	O YES	ONO				
Neuromuscular blocking agen	its? OYES ONO OUnkno	wn							
Other intervention(s) or proce	edure(s)? OYES ONO OU	Inknown If	YES, Specify:						
LABORATORY RESULTS (on	admission. on any admissi	on to ICU. t	hen daily) – complete every	ı line					
DATE OF ASSESSMENT (DD)			•••••	·					
LABORATORY RESULTS (*re			•						
Record the worst value betwe	•	f assessmer	nt (if Not Available write 'N/A		T				
Parameter	Value*	Not done	Parameter	Value*	Not done				
Haemoglobin (g/L)		0	Urea (BUN) (mmol/L)		0				
WBC count (x10 ⁹ /L)		0	Lactate (mmol/L)		0				
Lymphocyte count (10 ⁹ /L)		0	Creatinine (µmol/L)		0				
Neutrophil count (10 ⁹ /L)		0	Sodium (mmol/L)		0				

- arameter	7 4.4.0		· arameter	· a.a.c	
Haemoglobin (g/L)		0	Urea (BUN) (mmol/L)		0
WBC count (x10 ⁹ /L)		0	Lactate (mmol/L)		0
Lymphocyte count (10 ⁹ /L)		0	Creatinine (µmol/L)		0
Neutrophil count (10 ⁹ /L)		0	Sodium (mmol/L)		0
Haematocrit (%)		0	Potassium (mmol/L)		0
Platelets (x10 ⁹ /L)		0	Procalcitonin (ng/mL)		0
APTT (seconds))		0	CRP (mg/L)		0
APTR		0	LDH (U/L)		0
PT (seconds)		0	Creatine kinase (U/L)		0
INR		0	Troponin I (ng/mL)		0
ALT/SGPT (U/L)		0	D-dimer (mg/L)		0
Total bilirubin (μmol/L)		0	Ferritin (ng/mL)		0
AST/SGOT (U/L)		0	IL-6 (pg/mL)		0
Glucose (mmol/L)		0	Fibrinogen (mg/dl)		0





MODULE 3: OUTCOME CASE REPORT FORM

TREATMENT: At ANY time during hospitalisation, did the patient receive/undergo:								
Any Oxygen therapy? OYES ONO OUnknown If YES, total duration:days OUnknown								
Maximum O ₂ flow volume: O	<2 L/min O 2-5	L/min O 6-10 L/min G	O 11-15 L/min O >15 L/min					
Non-invasive ventilation? (Any)	OYES ONO O	Unknown	If YES, total duration:	_days O Unknown				
Invasive ventilation? (Any)	OYES ONO O	Unknown	If YES, total duration:	_days O Unknown				
High flow nasal oxygen	OYES ONO O	Unknown	If YES, total duration:	_days O Unknown				
Prone Positioning?	OYES ONO O	Unknown						
Inhaled Nitric Oxide?	OYES ONO O	Unknown						
Tracheostomy inserted?	OYES ONO O	Unknown						
Extracorporeal support (ECMO)?	OYES ONO O	Unknown	If YES, total duration:	days O Unknown				
Renal replacement therapy (RRT)	or dialysis? O	YES O NO O Unknown						
Inotropes/vasopressors?	OYES ONO O	Unknown						
ICU or High Dependency Unit adm	ission? OYES C	ONO OUnknown	If YES, total duration:	days O Unknown				
If YES, date of ICU	J admission:	[_D_](_D_]/(_M_)	[_M_]/[_2_][_0_][_Y_][_Y_]	OUnknown				
date of ICU	J discharge:	[_D_]/[_M_]	[_M_]/[_2_][_0_][_Y_][_Y_]	OUnknown				

COMPLICATIONS: At any time during hospitalisation did the patient experience: (Unk = Unknown)						
Viral pneumonia/pneumonitis	OYES ONO OUn	Meningitis / Encephalitis	OYES ONO OUnk			
Bacterial pneumonia	OYES ONO OUN	k Bacteremia	OYES ONO OUnk			
Acute Respiratory Distress Syndrome	OYES ONO OUN	k Coagulation disorder / DIC	OYES ONO OUnk			
Pneumothorax	OYES ONO OUN	k Pulmonary Embolism	OYES ONO OUnk			
Pleural effusion	OYES ONO OUN	k Deep Vein Thrombosis	OYES ONO OUnk			
Cryptogenic organizing pneumonia (COP)	OYES ONO OUN	dk Other thromboembolism (not PE or DVT)	OYES ONO OUnk			
Bronchiolitis	OYES ONO OUN	k Anemia	OYES ONO OUnk			
Cardiac arrest	OYES ONO OUN	k Rhabdomyolysis / Myositis	OYES ONO OUnk			
Myocardial infarction	OYES ONO OUN	k Acute renal injury/ Acute renal failure	OYES ONO OUnk			
Cardiac ischaemia	OYES ONO OUN	k Gastrointestinal haemorrhage	OYES ONO OUnk			
Cardiac arrhythmia	OYES ONO OUN	k Pancreatitis	OYES ONO OUnk			
Myocarditis / Pericarditis	OYES ONO OUN	k Liver dysfunction	OYES ONO OUnk			
Endocarditis	OYES ONO OUN	k Hyperglycemia	OYES ONO OUnk			
Cardiomyopathy	OYES ONO OUN	k Hypoglycemia	OYES ONO OUnk			
Congestive heart failure	OYES ONO OUN	k Other	OYES ONO OUnk			
Seizure	OYES ONO OUN	k If YES, specify:				
Stroke / Cerebrovascular accident	OYES ONO OUN	k				





MODULE 3: OUTCOME CASE REPORT FORM

DIAGNOSTICS
Section 1: RESPIRATORY VIRUS PCR TESTING
SARS-CoV-2 (COVID-19): OPositive ONegative ONot done OUnknown
Was other pathogen testing done during this illness episode? OYES (complete section) ONO OUnknown
Influenza: OPositive ONegative ONot done OUnknown
If Positive: OA-not typed OA/H3N2 OA/H1N1pdm09 OA/H7N9 OA/H5N1 OB OOther:OUnk
Respiratory Syncytial Virus (RSV): OPositive ONegative ONot done OUnknown
Adenovirus: OPositive ONegative ONot done OUnknown
Section 2: BACTERIAL TESTING
Bacteria: OPositive ONegative ONot done If Positive, specify:OUnknown
Other pathogen/s detected: OYES ONO OUnknown If YES, specify all:OUnknown
Section 3: RADIOLOGY
Clinical pneumonia diagnosed? OYES ONO OUnknown
Chest X-Ray performed? OYES ONO OUnknown If Yes: Were infiltrates present? OYES ONO OUnknown
CT performed? OYES ONO OUnknown If Yes: Were infiltrates present? OYES ONO OUnknown

Section 4: PATHOGEN TESTING DETAILS

Collection Date (DD/MM/YYYY)	Biospecimen Type	Laboratory test Method	Result	Pathogen Tested/Detected
_D_D_/_MM_/20_YY_	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFECES/rectal swab OHero, Specify:	OPCR OCulture OOther, Specify:	OPositive ONegative OUnknown	
_D_D_/_MM_/20_Y_Y_	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFECES/rectal swab OBlood OOther, Specify:	OPCR OCulture OOther, Specify:	OPositive ONegative OUnknown	
DD/_MM_/20_YY_	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFECES/rectal swab OHeces/rectal swab OHeces/rectal swab OHeces/rectal swab	OPCR OCulture OOther, Specify:	OPositive ONegative OUnknown	
_DD/_MM/20YY	ONasal/NP swab OCombined nasal/NP+throat swab OSputum OBAL OFA OFA OCOMBINE OFA OCOMBINE OFA OCOMBINE OFA OCOMBINE OCOMB	OPCR OCulture OOther, Specify:	OPositive ONegative OUnknown	





MODULE 3: OUTCOME CASE REPORT FORM

MEDICATION: While hospitalised or at discharge, were any of the following administered? (Unk=Unknown)
ANTIVIRAL OR COVID-19 TARGETED AGENT? OYES ONO OUnknown If YES, specify (all):
□ Ribavirin Date commenced[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] OUnk Duration:days OUnk
□ Lopinavir/Ritonavir Date commenced [□_][_□_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] OUnk Duration: days OUnk
□ Remdesivir (Veklury) Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] OUnk Duration: days OUnk
□ Interferon alpha Date commenced [□][□]/[M][M]/[2][0][Y][Y] OUnk Duration: days OUnk
☐ Interferon beta Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] OUnk Duration: days OUnk
☐ Chloroquine/hydroxychloroquine:
Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
□ Interleukin-6 (IL-6) inhibitor
Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Ounk Duration:days Ounk
□ Convalescent plasma Date commenced [□][□]/[M][M]/[2][0][Y][Y] OUnk Duration:days OUnk
□ Anti-influenza anti-viral IF YES which: □Oseltamivir (Tamiflu®) □ Zanamivir O Unk
Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Ounk Duration:days Ounk
□ Other Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] OUnk Duration:days OUnk
ANTIBIOTIC? OYES ONO OUnknown If yes, specify all:
Agent 1: Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Duration: days OUnk
Agent 2: Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Duration: Ounk
Agent 3: Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Duration: days OUnk
CORTICOSTEROID? OYES ONO OUnknown
If YES: Dexamethasone? OYES ONO OUnknown
If YES, check all that apply:
☐ 6mg once per day (od)? OYES ONO OUnknown If YES, Route: ☐ Oral ☐ Intravenous OUnk
If YES, Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Duration : days O Unk
☐ other dose or frequency? OYES ONO OUnknown If YES, Route: ☐ Oral ☐ Intravenous OUnk
If YES, Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Duration : days O Unk
If YES: Other corticosteroid? OYES ONO OUnknown
If YES: Which steroid: □ Prednisolone □ Hydrocortisone □ Methylprednisolone □ Other
Route: □ Oral □ Intravenous OUnk





MODULE 3: OUTCOME CASE REPORT FORM

MEDICATION (continued):
ANTICOAGULATION? OYES ONO OUNK
If YES: Agent:
Route: ☐ Subcutaneous ☐ Intravenous (IV) OUnk
Indication: ☐ therapeutic (treatment of DVT/PE) ☐ enhanced prophylaxis for COVID-19 ☐ routine inpatient prophylaxis ☐ Unk
ANTIFUNGAL AGENT? OYES ONO OUNK
OTHER treatments administered for COVID-19 including experimental or compassionate use? OYES ONO OUNK
If YES, specify agent and timing of administration:
Agent 1:
Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Ounk Duration: days Ounk
Agent 2:
Date commenced [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] OUnk Duration: days OUnk
Agent 3:
Date commenced [D][D]/[M][M]/[2][0][Y][Y] OUnk Duration: days OUnk
OUTCOME
Was patient diagnosed with Covid-19? OYES ONO OUnknown
If yes, was the diagnosis based on: Olaboratory confirmation O clinical assessment
Outcome: ODischarged alive OHospitalised OTransfer to other facility ODeath OPalliative discharge OUnknown
Outcome date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
If alive at outcome date:
Ability to self-care at discharge versus before illness: OSame as before illness OWorse OBetter OUnknown
Post-discharge treatment: Oxygen therapy? OYES ONO OUnknown
Ongoing health care needs relating to this admission for COVID-19: OYES ONO OUnknown
Ongoing health care needs NOT related to COVID episode: OYES ONO OUnknown
Medically fit for discharge (COVID-19 resolved) but remains in hospital for other reason (e.g. awaiting suitable care in community,
resident in long term health care or mental health facility): OYES ONO OUnknown